Labcorp (LH) CMO Amy Summy receives stock options and RSU awards

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported new equity awards on February 10, 2026. She received 1,900 non-qualified stock options with an exercise price of $284.50 per share under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and cover 1,900 shares of common stock.

She also acquired 620 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, she directly holds 1,534 RSUs in total. The filing reflects routine compensation-related awards rather than open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Summy Amy B.

Role EVP, Chief Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	1,900	$0.00	--
Grant/Award	Restricted Stock Unit	620	$0.00	--

Holdings After Transaction: Non-qualified Stock Options — 1,900 shares (Direct); Restricted Stock Unit — 1,534 shares (Direct)

Footnotes (1)

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The option vests in three equal annual installments beginning on the date reflected in this column. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Summy Amy B.

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Options(1)	$284.5	02/10/2026		A		1,900		02/10/2027(2)	02/09/2036	Common Stock	1,900	$0	1,900	D
Restricted Stock Unit	(3)	02/10/2026		A		620		(4)	(4)	Common Stock	620	$0	1,534(5)	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Amy B. Summy	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Labcorp (LH) report for Amy B. Summy?

Amy B. Summy reported receiving equity awards, not market trades. She was granted 1,900 non-qualified stock options and 620 Restricted Stock Units as part of her executive compensation on February 10, 2026.

How many stock options did the Labcorp (LH) CMO receive in this Form 4?

The EVP and Chief Marketing Officer received 1,900 non-qualified stock options. These options were granted under Labcorp’s 2025 Omnibus Incentive Plan and relate to 1,900 shares of common stock, vesting over three years in equal annual installments.

What are the key terms of Amy B. Summy’s Labcorp (LH) stock options?

She received 1,900 non-qualified stock options with a $284.50 exercise price per share. The options vest in three equal annual installments starting on the February 10, 2026 grant date and expire on February 9, 2036, if not exercised.

How many Restricted Stock Units were granted to the Labcorp (LH) executive?

She was granted 620 Restricted Stock Units. Each RSU represents the right to receive one share of Labcorp common stock, vesting in three equal annual installments beginning on February 10, 2027, subject to continued service and plan conditions.

What is Amy B. Summy’s total Labcorp (LH) RSU holding after this grant?

After the February 10, 2026 grant, Amy B. Summy beneficially owns 1,534 Restricted Stock Units. This figure reflects the aggregate number of RSUs directly held by her following the reported compensation-related award.

Are these Labcorp (LH) insider transactions open-market buys or sells?

No, the transactions are equity awards, not open-market trades. The Form 4 uses transaction code “A,” indicating grant or other acquisition of 1,900 options and 620 RSUs as part of her executive compensation package.